Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Chris Garabedian's incubator leads Series A funding for gene therapy manufacturer/developer combo

5 years ago

J&J-partnered MeiraGTx aims at Biogen with new eye gene therapy data

5 years ago

Engineering an on/off switch for CAR-T out of yeast and Jurassic Park

5 years ago

Playing catch-up, Roche outlines plans for a PhIII hemophilia A program — next year

5 years ago

Merck dangles up to $425 million to team with Flagship’s Foghorn Therapeutics on drugging the shape of DNA

5 years ago

John Reed brings NK cells into Sanofi's CD38 rivalry with J&J — and offers thumbs up for Kiadis' new focus

5 years ago

Flagship execs take a lesson from nature to master ‘gene writing,’ launching a star-studded biotech with big ambitions to cure disease

5 years ago

RA Capital doubles down on Siddhartha Mukherjee's vision for a new cell engineering approach, leading Vor's $110M Series B

5 years ago

A booming Dragonfly is taking its TriNKETs to Copenhagen as the latest Bristol Myers pact spurs expansion plans — outside the US

5 years ago

Ionis, leading MS researcher throw antisense at a new type of brain cells

5 years ago

Freeline nabs $120M, eyes IPO as its gene therapy comes into focus

5 years ago

Sekar Kathiresan showcases historic monkey data in hunt for a once-and-done gene editing approach to prevent heart attacks

5 years ago

Second death triggers hold on Astellas' $3B gene therapy biotech's lead program, raising fresh concerns about AAV

5 years ago

Novartis-backed Poseida is packing in the cash for its next-gen CAR-T work, adding a $110M venture raise on top of its newly-refiled IPO

5 years ago

Out of jobs, a pair of early cell therapy executives went to Seoul, came back with a new company, $70M and a plan to leapfrog natural killer competitors

5 years ago

In an unexpected twist, CSL buys worldwide rights to uniQure's PhIII hemophilia B gene therapy in $2B-plus deal

5 years ago

With its campus expanding as gene therapy booms, Aldevron brings in a top exec from a medtech giant to steer the course

5 years ago

What’s it take to raise $700M-plus for a biotech startup? Steve Harr has some thoughts on that

5 years ago

Sarepta expands gene therapy toolkit, bets $72.5M to hitch a ride on Codiak's exosome tech

5 years ago

Cell and gene therapy 2.0 dominates latest round of biotech IPOs in scramble for a $300M-plus Nasdaq windfall

5 years ago

As BioMarin’s lead rival wanes, Pfizer and Sangamo post a promising update for hemophilia A gene therapy

5 years ago

Two Bay Area upstarts out to deliver on cell therapy 2.0 join forces on a quest: pursuing a Holy Grail in oncology R&D

5 years ago

BioMarin spells out a troubling slide in Factor VIII levels for its big blockbuster contender valrox

5 years ago

Eyeing a hot IPO market, 4DMT tops up its cash reserves and preps a leap into the clinic with bespoke gene therapy vectors

5 years ago

First page Previous page 45 46 474849 50 51 Next page Last page